Merck’s KEYTRUDA bags FDA nod for platinum-resistant ovarian cancer
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
KEYTRUDA QLEX is contraindicated in patients with known hypersensitivity to its components
Profit before tax jumped 64% to Rs. 226 crore, while the company maintained robust investment in innovation with net R&D spend of Rs. 249 crore
The Profit After Tax (PAT) for Q3 FY26 was Rs 49.68 crore, compared to Rs 46.78 crore in Q3 FY25
The milestone means more than 1,000 men are now enrolled across both Phase 3 programs
Launched in August 2025, GSK India’s Oncology business is rapidly gaining momentum
The acquisition brings Lilly a novel in vivo cell therapy platform built around engineered circular RNA and proprietary lipid nanoparticles
The new OMR facility, located in Chennai’s medical hub, is close to leading hospitals and offers excellent road and air connectivity
Anand Chemiceutics serves over 1,500 laboratories, hospitals, and government institutions
Revenue from operations surged 30% year-on-year to Rs. 68,645 million
Subscribe To Our Newsletter & Stay Updated